Vms1 is a Novel Protein Critical for Mitochondrial Maintenance
Project Number5R00AR059190-05
Former Number4K99AR059190-03
Contact PI/Project LeaderTAYLOR, ERIC B
Awardee OrganizationUNIVERSITY OF IOWA
Description
Abstract Text
Project Summary
Mitochondrial dysfunction in skeletal muscle has devastating consequences including muscle wasting,
exercise intolerance, and insulin resistance. We have discovered that a novel, highly conserved protein is
critical for maintenance of mitochondrial function and cellular energy homeostasis in yeast and
mammalian cells. We have designated this protein Lifespan-associated Mitochondrial Stress-responsive 1
(Lms1). Our data from yeast support a model whereby Lms1 recruits components of the ubiquitin
proteasome system to mitochondria to extract damaged proteins and present them to the proteasome for
degradation. The purpose of this research is to determine the function and mechanism of Lms1 action in
skeletal muscle using cultured muscle cells and Lms1 knockout mice. For Specific Aims 1 and 2, which
span the K99 and R00 phases, the candidate will investigate the role of Lms1 in cultured muscle cells.
Studies in Aim 1 will determine whether mammalian Lms1 recruits the ubiquitin proteasome system to
mitochondria as part of a mitochondrial protein quality control system. Studies in Aim 2 will determine
the nature of mitochondrial defects observed with Lms1 depletion in muscle cells. Completion of the sub-
aims proposed during the K99 phase will provide the candidate with training in aspects of cellular and
molecular biology necessary to independently complete the R00 phase. For Specific Aims 3 and 4, the
candidate will determine the role of Lms1 at the mammalian organismal level. For Aim 3 (K99 phase), the
candidate will examine an Lms1 knockout mouse for mitochondrial dysfunction in heart muscle and begin
studies in skeletal muscle. For Aim 4 (R00 phase), the candidate will examine an Lms1 skeletal muscle-
specific knockout mouse for mitochondrial dysfunction and consequences including exercise intolerance,
muscle wasting, and insulin resistance. Experiments proposed in Aim 3 will provide the candidate with
the training in mitochondrial physiology necessary to independently complete Aim 4 during the R00
phase. Collectively, these experiments seek to establish a mechanistic basis for Lms1 action in cultured
muscle cells and to extend these findings to mice where they will be tested for physiologic relevance. These
studies will provide novel insight into the regulation of mitochondria in skeletal muscle.
Public Health Relevance Statement
Public Health Relevance
Mitochondrial dysfunction in skeletal muscle has devastating consequences including muscle wasting,
exercise intolerance, and insulin resistance. We have discovered that a novel protein termed Lms1 is
important for maintaining mitochondrial function. These studies will determine the role of Lms1 in
maintaining mitochondrial function in skeletal muscle. __SpecificAimsTextDelimiter__
SPECIFIC AIMS
Mitochondrial dysfunction in skeletal muscle has devastating consequences including muscle wasting,
exercise intolerance, and insulin resistance. Using yeast, C. elegans, and cultured mammalian cells, we
have discovered that a novel, highly conserved protein is critical for maintenance of mitochondrial
function and cellular energy homeostasis. We have designated this protein Lifespan-associated
Mitochondrial Stress-responsive 1 (Lms1). In yeast, Lms1 translocates to mitochondria upon application
of mitochondrial stress, Lms1 physically associates with Cdc48 and Npl4, which are components of the
ubiquitin proteasome system, and LMS1 deletion causes mitochondrial accumulation of polyubiquitinated
proteins and respiratory failure. We propose a model wherein Lms1 recruits Cdc48 and Npl4 to
mitochondria to extract damaged proteins for degradation by the proteasome, thereby linking
mitochondria to the proteasome as part of a mitochondrial protein quality control system. Lms1 depletion
in cultured mammalian cells decreases cellular ATP content and mitochondrial membrane potential and
initial experiments with an Lms1 knockout (Lms1-/-) mouse suggest the mitochondrial phenotype observed
in model systems extends to the mammalian organismal level. Herein I propose to determine the function
and mechanism of Lms1 action in skeletal muscle.
Specific AIM #1: To determine the mechanism of Lms1 action in cultured muscle cells.
In yeast, Lms1 translocates to mitochondria under mitochondrial stress. In yeast, Lms1 physically
associates with Cdc48 and Npl4 and appears to recruit them to mitochondria to extract damaged and
polyubiquitinated proteins as part of a mitochondrial protein quality control system. Using cultured
muscle cells we will: 1) Determine whether mitochondrial stress causes Lms1 to translocate to
mitochondria; 2) Determine whether Lms1 physically associates with p97 (Cdc48 in yeast) and Npl4 and
comprehensively identify the components of the Lms1 protein complex; 3) Confirm candidate Lms1
interacting proteins and begin to study their roles in mitochondrial function; 4) Determine whether Lms1
depletion causes accumulation of mitochondrial polyubiquitinated proteins.
Specific AIM #2: To determine the nature of the mitochondrial defects caused by Lms1
depletion in cultured muscle cells. Lms1 knockdown in C2C12 cells causes decreased ATP content
and mitochondrial membrane potential. The goals of this aim are to determine whether Lms1 depletion in
cultured muscle cells results in: 1) Decreased mitochondrial respiratory capacity and/or coupling; 2)
Physical damage to mitochondria including protein carbonylation and lipid peroxidation; 3) Increased
mitochondrial H2O2 emission, 4) Decreased activities of electron transport chain respiratory complexes; 5)
Systematic changes in the composition of the mitochondrial proteome.
Specific AIM #3: To determine the consequences of Lms1 deletion in mice. We have generated
a germline Lms1 knockout mouse (Lms1-/-). These mice display decreased spontaneous activity and
elevated oxygen consumption to activity ratios, characteristics consistent with known models of
mitochondrial dysfunction. We will: 1) perform a general observational characterization of the Lms1-/-
mouse; and 2) test the hypothesis that heart muscle from Lms1-/- mice has decreased respiratory and ATP
generating capacity.
Specific AIM #4: To determine the consequences of selective Lms1 deletion in mouse
skeletal muscle. Unequivocally determining the specific consequences of Lms1 deletion in skeletal
muscle will require selective deletion. We will generate Lms1 skeletal muscle specific knockout mice
(Lms1SM-/-) and determine whether: 1) In vivo, Lms1SM-/- mice have decreased exercise tolerance, skeletal
muscle strength, and insulin sensitivity; 2) Ex vivo, skeletal muscle from Lms1SM-/- mice has reduced
respiratory capacity, increased H2O2 emission, and decreased insulin-stimulated glucose uptake; 3)
Mitochondria in Lms1SM-/- mouse skeletal muscle accumulate damaged and polyubiquitinated proteins
and exhibit gross morphological defects detectable by electron microscopy.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
062761671
UEI
Z1H9VJS8NG16
Project Start Date
08-September-2012
Project End Date
31-August-2016
Budget Start Date
01-September-2014
Budget End Date
31-August-2016
Project Funding Information for 2014
Total Funding
$244,019
Direct Costs
$167,554
Indirect Costs
$76,465
Year
Funding IC
FY Total Cost by IC
2014
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$244,019
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R00AR059190-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R00AR059190-05
Patents
No Patents information available for 5R00AR059190-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R00AR059190-05
Clinical Studies
No Clinical Studies information available for 5R00AR059190-05
News and More
Related News Releases
No news release information available for 5R00AR059190-05
History
No Historical information available for 5R00AR059190-05
Similar Projects
No Similar Projects information available for 5R00AR059190-05